# Vinorelbine

Source: https://onco.cc/drugs/vinorelbine/  
OnCo record `vinorelbine` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vinorelbine is a vinca chemotherapy for lung and breast cancer, available orally, and is now part of maintenance therapy that improved survival in childhood rhabdomyosarcoma.

## Summary

Vinorelbine is a semi-synthetic vinca alkaloid that binds tubulin and blocks mitosis, with relative selectivity for mitotic over axonal microtubules and therefore less neuropathy than older vincas. It was approved in the EU in 1989 and in the US in 1994 for advanced NSCLC as a single agent or with cisplatin, and cisplatin-vinorelbine was the adjuvant regimen in the ANITA and JBR.10 trials that established post-operative chemotherapy in lung cancer. It is also used in metastatic breast cancer, mesothelioma and Hodgkin lymphoma salvage, and its oral formulation allows metronomic low-dose schedules. In children with high-risk rhabdomyosarcoma, maintenance vinorelbine with cyclophosphamide improved overall survival in the EpSSG RMS 2005 trial. Neutropenia is the main toxicity. Vinorelbine is an old chemotherapy that keeps finding new roles.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-08
- Tags: gap-fill; generic
- Brand: Navelbine
- Modality: Semi-synthetic vinca alkaloid
- Mechanism: Tubulin-binding antimitotic with relative selectivity for mitotic over axonal microtubules (less neuropathy).
- Approvals: US 1994: Advanced NSCLC as single agent or with cisplatin; EU 1989: NSCLC, metastatic breast cancer

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Vinorelbine
- Label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=vinorelbine

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/), [Rhabdomyosarcoma](https://onco.cc/cancers/rhabdomyosarcoma/), [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- companies: [Pierre Fabre](https://onco.cc/companies/pierre-fabre/)
- trials: [A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer](https://onco.cc/trials/nct05999994/), [A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC](https://onco.cc/trials/nct06908304/), [A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)](https://onco.cc/trials/nct06343948/), [A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o](https://onco.cc/trials/nct06435429/), [A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer](https://onco.cc/trials/nct06202261/), [A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With](https://onco.cc/trials/nct06459180/), [Anetumab ravtansine versus vinorelbine in relapsed mesothelin-positive pleural mesothelioma](https://onco.cc/trials/anetumab-vs-vinorelbine-mpm/), [ANITA (Adjuvant Navelbine International Trialist Association)](https://onco.cc/trials/anita/), [Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)](https://onco.cc/trials/nct04639986/), [ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer](https://onco.cc/trials/nct07007559/), [Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients](https://onco.cc/trials/nct06690840/), [Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery](https://onco.cc/trials/nct00005838/), [Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct06632327/), [Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer](https://onco.cc/trials/nct06229067/), [EMBRACA](https://onco.cc/trials/embraca/), [IALT (International Adjuvant Lung Cancer Trial)](https://onco.cc/trials/ialt/), [JBR.10 (NCIC CTG)](https://onco.cc/trials/jbr-10/), [KEYNOTE-119](https://onco.cc/trials/keynote-119/), [LACE (Lung Adjuvant Cisplatin Evaluation) pooled analysis](https://onco.cc/trials/lace-pooled-analysis/), [OlympiAD](https://onco.cc/trials/olympiad/), [Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer](https://onco.cc/trials/nct04963595/), [Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer](https://onco.cc/trials/nct06081959/), [Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [](https://onco.cc/trials/nct02486718/), [SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer](https://onco.cc/trials/nct03262935/), [Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients](https://onco.cc/trials/nct02579564/), [Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated](https://onco.cc/trials/nct06908993/)
- key papers: [Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group](https://onco.cc/key-papers/paper-lace-adjuvant-cisplatin-pooled-analysis-jco-2008/)
- drugs: [Anetumab ravtansine](https://onco.cc/drugs/anetumab-ravtansine/), [Vindesine](https://onco.cc/drugs/vindesine/), [Vinflunine](https://onco.cc/drugs/vinflunine/)
- pathways: [Mitosis & the spindle assembly checkpoint](https://onco.cc/pathways/mitotic-spindle-checkpoint/)

---
JSON: https://onco.cc/api/v1/entities/vinorelbine.json